A Bcl-xL transgene promotes malignant conversion of chemically initiated skin papillomas.

The role of apoptosis in the pathogenesis of skin cancer was analyzed in mice bearing a Bcl-xL transgene expressed under the control of the keratin 14 promoter. No spontaneous tumors developed in the skin of these transgenic mice. Bcl-xL transgenics also failed to develop skin lesions following treatment with the chemical mutagen 9,10-dimethyl-1,2-benzanthracene, or the tumor promoter O-tetradecanoylphorbol-13-acetate. However, Bcl-xL transgenics developed a two-fold greater number of benign papillomas than control littermates following treatment with the combination of 9,10-dimethyl-1,2-benzanthracene and O-tetradecanoylphorbol-13-acetate. More significantly, Bcl-xL transgenic mice developed invasive squamous cell carcinoma earlier and more frequently than wild-type controls in response to the chemical agents. These data suggest that Bcl-xL cannot functionally substitute for a mutagenic initiator or mitogenic promoter in tumorigenesis. In contrast, Bcl-xL overexpression can dramatically increase the malignant conversion rate of benign tumors, suggesting that inhibition of apoptosis can contribute to tumor progression.

[1]  E. Fuchs,et al.  Bcl-x expression influences keratinocyte cell survival but not terminal differentiation. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[2]  S. Weitzman,et al.  Influence of oxygen radical injury on DNA methylation. , 1997, Mutation research.

[3]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[4]  S. Gauny,et al.  Suppression of apoptosis by Bcl-2 or Bcl-xL promotes susceptibility to mutagenesis. , 1996, Oncogene.

[5]  S. Korsmeyer,et al.  Molecular thanatopsis: a discourse on the BCL2 family and cell death. , 1996, Blood.

[6]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[7]  L. Chin,et al.  Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.

[8]  M. Gottesman,et al.  Gene-specific DNA repair and steady state transcription of the MDR1 gene in human tumor cell lines. , 1996, Oncogene.

[9]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[10]  C. Rudin,et al.  Expression of bcl-xL can confer a multidrug resistance phenotype. , 1995, Blood.

[11]  S. Morris,et al.  Programmed cell death and mutation induction in AHH-1 human lymphoblastoid cells exposed to m-amsa. , 1995, Mutation research.

[12]  J. Mccormick,et al.  Site-specific rates of excision repair of benzo[a]pyrene diol epoxide adducts in the hypoxanthine phosphoribosyltransferase gene of human fibroblasts: correlation with mutation spectra. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[13]  G. Evan,et al.  Apoptosis and the cell cycle. , 1995, Current opinion in cell biology.

[14]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[15]  D. Housman,et al.  Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[16]  G. Evan,et al.  Oncogenes and cell death. , 1994, Current opinion in genetics & development.

[17]  D. Roop,et al.  Dissecting molecular carcinogenesis: development of transgenic mouse models by epidermal gene targeting. , 1994, Advances in cancer research.

[18]  T. Jacks,et al.  Sunburn and p53 in the onset of skin cancer , 1994, Nature.

[19]  L. Donehower,et al.  In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. , 1993, Oncogene.

[20]  R. Tennant,et al.  Chemically induced skin carcinogenesis in a transgenic mouse line (TG.AC) carrying a v-Ha-ras gene. , 1993, Carcinogenesis.

[21]  D. Roop,et al.  Induction of epidermal hyperplasia, hyperkeratosis, and papillomas in transgenic mice by a targeted v‐Ha‐ras oncogene , 1993, Molecular carcinogenesis.

[22]  E. Fuchs,et al.  Transgenic overexpression of transforming growth factor alpha bypasses the need for c-Ha-ras mutations in mouse skin tumorigenesis , 1992, Molecular and cellular biology.

[23]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[24]  M. Raff,et al.  Social controls on cell survival and cell death , 1992, Nature.

[25]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[26]  J. DiGiovanni,et al.  Multistage carcinogenesis in mouse skin. , 1992, Pharmacology & therapeutics.

[27]  R. Cardiff,et al.  v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Strasser,et al.  Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2 , 1990, Nature.

[29]  B. Ames,et al.  Chemical carcinogenesis: too many rodent carcinogens. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[30]  B. Ames,et al.  Too many rodent carcinogens: mitogenesis increases mutagenesis. , 1990, Science.

[31]  A. Balmain,et al.  Skin hyperkeratosis and papilloma formation in transgenic mice expressing a ras oncogene from a suprabasal keratin promoter , 1990, Cell.

[32]  Peter K. Vogt,et al.  Obligatory wounding requirement for tumorigenesis in v-jun transgenic mice , 1990, Nature.

[33]  B. Ames,et al.  Oxidative damage to DNA during aging: 8-hydroxy-2'-deoxyguanosine in rat organ DNA and urine. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. Hanahan,et al.  Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.

[35]  E. Fuchs,et al.  Tissue-specific and differentiation-specific expression of a human K14 keratin gene in transgenic mice. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[36]  E. Wagner,et al.  c-fos expression interferes with thymus development in transgenic mice , 1988, Cell.

[37]  S. Yuspa,et al.  Chemical carcinogenesis: from animal models to molecular models in one decade. , 1988, Advances in cancer research.

[38]  B. Vogelstein,et al.  Clonal analysis of human colorectal tumors. , 1987, Science.

[39]  K. Danno,et al.  SUNBURN CELL: FACTORS INVOLVED IN ITS FORMATION. , 1987, Photochemistry and photobiology.

[40]  A. Balmain,et al.  Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis , 1986, Nature.

[41]  S. Yuspa,et al.  Induction of papillomas with a high probability of conversion to malignancy. , 1985, Carcinogenesis.

[42]  P. Cerutti.  Prooxidant states and tumor promotion. , 1985, Science.

[43]  R. Tarone,et al.  Malignant conversion of mouse skin tumours is increased by tumour initiators and unaffected by tumour promoters , 1983, Nature.

[44]  B. McKnight,et al.  Evidence for a new model of tumor progression from carcinogenesis and tumor promotion studies with 7-bromomethylbenz[a]anthracene. , 1983, Cancer research.

[45]  P. Strickland.  Tumor induction in Sencar mice in response to ultraviolet radiation. , 1982, Carcinogenesis.

[46]  T. Slaga,et al.  Comparison of two-stage epidermal carcinogenesis initiated by 7,12-dimethylbenz(a)anthracene or N-methyl-N'-nitro-N-nitrosoguanidine in newborn and adult SENCAR and BALB/c mice. , 1981, Cancer research.

[47]  R. Albert,et al.  Regression kinetics of mouse skin papillomas. , 1976, Cancer research.

[48]  R. Boutwell,et al.  The function and mechanism of promoters of carcinogenesis. , 1974, CRC critical reviews in toxicology.

[49]  E. J. Andrews.  Evidence of the nonimmune regression of chemically induced papillomas in mouse skin. , 1971, Journal of the National Cancer Institute.

[50]  R. Baserga,et al.  The Life and Progression of Induced Skin Tumors in Mice , 1953, British Journal of Cancer.